Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Viking Therapeutics ( (VKTX) ) has provided an announcement.
Viking Therapeutics announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of the VK2735 tablet formulation for obesity treatment. The trial demonstrated significant weight loss in patients, with up to 12.2% reduction in body weight over 13 weeks compared to placebo, and showed the treatment to be safe and well-tolerated, with most adverse events being mild or moderate.
The most recent analyst rating on (VKTX) stock is a Buy with a $71.00 price target. To see the full list of analyst forecasts on Viking Therapeutics stock, see the VKTX Stock Forecast page.
Spark’s Take on VKTX Stock
According to Spark, TipRanks’ AI Analyst, VKTX is a Neutral.
Viking Therapeutics’ overall score reflects the typical profile of an early-stage biotech company. Strengths include a robust balance sheet and promising clinical trial results, but these are offset by high operational losses and cash burn. Technical indicators suggest short-term positive momentum, yet valuation concerns persist due to the absence of profitability. The earnings call provided a positive outlook with significant pipeline advancements.
To see Spark’s full report on VKTX stock, click here.
More about Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.
Average Trading Volume: 3,856,205
Technical Sentiment Signal: Buy
Current Market Cap: $4.5B
Find detailed analytics on VKTX stock on TipRanks’ Stock Analysis page.